RESOURCES

Blogs

Insight at the intersection of data science and real-world health

The Talking Room

Demystifying AI, LLMs and machine learning

Use Cases

How teams put the signals to work

Compliance Hub

Data integrity, ethical AI and regulatory standards

DrugVoice

Built to be defensible.

Compliance, ethics, and data integrity are part of the process.

TMLABS

About us

Where our proprietary models are trained, tested and refined

Articles & scientific publications

Peer-reviewed methodologies and validated outcomes

Latest paper

The New GLP-1 Consumer

Articles & Scientific Publications

DRUGVOICE

DrugVoice

Measure how your messaging lands and evidence what moved

SEE IT IN ACTION

Bring us a question you can’t answer.

We’ll show you what the conversation already contains, using your therapy area and your audience.

ABOUT US

About us

Where our proprietary models are trained, tested and refined

ESG

Responsible innovation and ethical data practice

WHO WE ARE

Data scientists who speak pharma.

A team built around one problem: making real-world conversation usable at scale.

Appointment of Head of Data Quality

Data insights firm Talking Medicines, specialist in ‘social intelligence’ for the pharmaceutical industry, has appointed Donna Lawson to the position of Head of Data Quality. A particularly good fit for the role, Donna brings with her over two decades’ experience within clinical data management.

Donna’s appointment follows a period of substantial growth for the Glasgow-based company, with £1.1 million funding secured in November 2020 and three senior appointments in 2021 so far. Talking Medicines continues to develop and scale up its AI-based data technology platform, PatientMetRx, which is designed to distil complex data from a range of sources and provide meaningful insights for the pharmaceutical sector.

Donna joins Talking Medicines from IQVIA Biotech where she was Director of Data Management and was previously Global Head of UK Data Management at ClinTec International. Areas of specialism have included data quality, overseeing the use of client data, strategic planning and implementing data protection and quality improvement.

Talking Medicines CEO, Jo Halliday, said: “We’re exceptionally pleased to be welcoming Donna to the team and we’ve been impressed with her passion for data, particularly the use of data within the pharmaceutical industry. Donna has managed many project teams from database development/implementation to final submissions to regulatory authorities and will play an important part in ensuring the data quality standard of our PatientMetRx product.

“High quality, reliable data is absolutely critical to what we do. Donna’s experience will be invaluable as we continue to develop our AI platforms and embark on our next stage of growth.”

Donna Lawson said: “The work that Talking Medicines is doing in making sense of complex data for the pharmaceutical industry is at the forefront of data technology and I’m excited to be joining the team and being part of the company’s journey.”

About Talking Medicines 

Talking Medicines is the world’s first social intelligence company designed specifically for the pharmaceutical industry. By structuring and translating the patient’s voice on social media into actionable intelligence, it helps pharma deliver a greater return on investment for marketing, and better health outcomes for patients.

 

Sign Up to Stay Ahead of Message Impact

Discover how Pharma marketeers are finally measuring which messages change HCP behavior. Our newsletter shares evidence-led insights powered by DrugVoice and the Message Resonance Score™ so you can predict and prove message impact—before prescriptions are written.

Subscribe on LinkedIn

Read More

#
$